STOCK TITAN

Moderna - MRNA STOCK NEWS

Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.

About Moderna

Moderna, Inc. is a commercial-stage biotechnology company renowned for pioneering messenger RNA (mRNA) therapeutics, a revolutionary in vivo drug modality that enables the body’s cells to produce human proteins and antibodies. This groundbreaking approach has transformed how medicines are developed, offering novel treatment avenues for infectious diseases, oncology, rare genetic disorders, and other serious conditions. By harnessing its proprietary mRNA platform, Moderna has established a comprehensive portfolio of potential therapeutics and vaccines, positioned at the nexus of science, technology, and healthcare innovation.

Innovative mRNA Technology Platform

The company’s core technology leverages synthetic mRNA to instruct patient cells to express therapeutic proteins. This innovative platform addresses traditionally undruggable targets and provides a versatile alternative to conventional therapies. With an extensive intellectual property estate that encompasses numerous patent applications and claims across novel nucleotide chemistries and drug compositions, Moderna’s expertise underpins its robust research and development pipeline. Its approach emphasizes rapid development, scalability, and the flexibility to target a wide array of disease conditions.

Clinical Pipeline and Therapeutic Areas

Moderna’s diversified clinical pipeline spans multiple therapeutic categories, including:

  • Infectious Diseases: The company gained widespread recognition for its development of an effective COVID-19 vaccine, which validated its mRNA technology on a global stage. It continues to evolve its respiratory vaccine portfolio with candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and other emerging infectious pathogens.
  • Oncology: Moderna is exploring mRNA-based immunotherapies designed to harness the immune system’s potential to target cancer cells, including individualized neoantigen therapies. These therapeutic approaches aim to offer precision treatment modalities in oncology.
  • Rare Diseases: The company’s strategy includes developing mRNA-based treatments for rare genetic disorders, where traditional drug modalities often fall short. By targeting metabolic disorders and other conditions with limited treatment options, Moderna is working toward addressing significant unmet medical needs.
  • Latent and Other Diseases: Beyond infectious and oncological applications, Moderna’s pipeline incorporates next-generation vaccines and therapeutics targeting latent viruses and other challenging medical conditions.

Market Position and Value Proposition

Positioned as a trailblazer in mRNA therapeutics, Moderna combines a deep understanding of biological mechanisms with advanced pharmaceutical science. Its core value proposition lies in the ability to quickly design and develop mRNA-based candidates, reducing both development timelines and manufacturing complexity relative to traditional modalities. This agility has not only provided a rapid response to emergent global health challenges but has also established the company as a significant player in the biotechnology sector.

Business Model and Operational Excellence

Moderna generates revenue through its commercialized vaccine products and ongoing clinical collaborations across various therapeutic areas. The company’s operational model is characterized by strategic partnerships, efficient research and development processes, and rigorous adherence to regulatory standards. Its focus on cost efficiencies and portfolio prioritization further enhances its competitive edge. This balanced approach underscores Moderna’s commitment to delivering innovative, scalable, and safe mRNA medicines.

Commitment to Scientific Rigor and Transparency

Underpinned by a culture of scientific excellence and continuous innovation, Moderna maintains a high standard of transparency and rigor in its research. The company’s clinical development programs are structured to provide clear evidence of safety and efficacy, supporting its authority in the biotech field. This commitment enables healthcare providers and analysts to gain a deep understanding of the interconnected dynamics within its research and development initiatives.

Summary

In summary, Moderna stands at the forefront of the mRNA revolution, with a proven platform that redefines traditional therapeutic approaches. Its comprehensive pipeline, covering infectious diseases, oncology, rare disorders, and beyond, is a testament to the transformative potential of mRNA technology. As a company deeply embedded within the biopharmaceutical landscape, Moderna continues to drive innovation, operational excellence, and advancements in patient care, reinforcing its role as a key contributor to the future of medicine.

Rhea-AI Summary

Lila Sciences, founded by Flagship Pioneering in 2023, has emerged with a groundbreaking scientific superintelligence platform and autonomous labs for life, chemical, and materials sciences. The company has secured $200 million in seed financing from multiple investors including Flagship Pioneering, General Catalyst, and ARK Venture Fund.

The platform combines generative AI with autonomous AI science units to scale and optimize experimentation across scientific domains. Early achievements include developing advanced LLMs, generating optimal genetic medicine constructs, discovering novel antibodies, and creating cost-effective green hydrogen catalysts.

Led by CEO Geoffrey von Maltzahn and a team of experts including Chief Scientist George Church and CTO Andrew Beam, Lila's platform will be available to partners in life and material sciences industries to accelerate solutions in human health and sustainability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
none
-
Rhea-AI Summary

Moderna (NASDAQ:MRNA) has received marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for mRESVIA, its RSV vaccine for adults 60 years and older. This marks Moderna's second approved product in the UK.

The vaccine, designed to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV), will be manufactured at the Moderna Innovation and Technology Centre in Oxfordshire. RSV significantly impacts UK elderly adults, causing 175,000 GP appointments, 14,000 hospitalizations, and 8,000 deaths annually in those 65 and older.

The approval is based on the Phase 3 ConquerRSV trial, which involved approximately 37,000 adults aged 60+ across 22 countries. No serious safety concerns were identified during the trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
-
Rhea-AI Summary

Moderna (Nasdaq: MRNA) has announced its upcoming participation in two major investor conferences in March 2025. The company will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5th at 9:10am ET, and at the Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11th at 1:30pm ET.

Investors and interested parties can access live webcasts of both presentations through the "Events and Presentations" section of Moderna's investor website at investors.modernatx.com. For those unable to attend the live events, replays of the webcasts will remain available on the company's website for at least 30 days following each presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
conferences
Rhea-AI Summary

YourBio Health and Flagship Pioneering have announced the appointment of Paul Owen as CEO of YourBio Health and CEO-Partner of Flagship Pioneering. Owen brings over 35 years of corporate leadership experience, most recently serving as Board Director and President of Oncodea.

YourBio Health's key product, the Touch-Activated Phlebotomy (TAP®) device, is the first push-button blood collection technology using microneedles for virtually painless blood draws. The technology has been implemented in clinical trials, diagnostic settings, and wellness applications, with millions of blood collections completed since its commercial launch.

The company has established partnerships with biopharmaceutical companies, genetic companies, and academic research hospitals. The announcement also includes concurrent appointments to YourBio's leadership team, adding expertise in medical device product innovation, clinical strategy, and commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
management
-
Rhea-AI Summary

Moderna (MRNA) reported Q4 2024 revenues of $1.0 billion with a GAAP net loss of $(1.1) billion and EPS of $(2.91). Full-year 2024 revenues were $3.2 billion with a net loss of $(3.6) billion and EPS of $(9.28). The company's Q4 Spikevax sales reached $923 million, while mRESVIA sales were $15 million.

For 2025, Moderna expects revenues between $1.5-2.5 billion and projects year-end cash balance of approximately $6 billion. The company has submitted three mRNA products for regulatory approval: next-generation COVID vaccine, RSV vaccine for adults 18-59, and a flu/COVID combination vaccine.

Cost reduction efforts resulted in a 27% decrease compared to 2023, with plans to remove nearly $1 billion in costs by end of 2025. The company maintains a strong cash position of $9.5 billion as of December 31, 2024, though down from $13.3 billion year-over-year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.35%
Tags
-
Rhea-AI Summary

Moderna (NASDAQ:MRNA) has announced it will host a live conference call and webcast on Friday, February 14, 2025, at 8:00 a.m. ET to present its fourth quarter and full year 2024 financial results, along with a corporate update. The webcast will be available in the "Events and Presentations" section of Moderna's investor website. Following the conference call, an archived version of the webcast will be accessible on the company's website for one year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.39%
Tags
conferences earnings
Rhea-AI Summary

Moderna (NASDAQ:MRNA) has secured a tender for supplying its mRNA COVID-19 vaccine in the European Union, Norway, and North Macedonia. The agreement allows 17 participating countries to access Moderna's vaccine for up to four years.

The company will provide various vaccine formats, including pre-filled syringes, which are preferred by healthcare providers as they can reduce administration errors and save time, potentially improving vaccination campaign efficiency.

This announcement follows the European Commission's marketing authorization granted in September 2024 for Moderna's updated COVID-19 mRNA vaccine Spikevax, which targets the SARS-CoV-2 variant JN.1. The vaccine is authorized for individuals six months of age and older.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
covid-19
-
Rhea-AI Summary

Moderna (NASDAQ:MRNA) has received ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The $590 million award, made through the Rapid Response Partnership Vehicle (RRPV) Consortium with BARDA funding, will support late-stage development, licensure of pre-pandemic vaccines, and expansion of clinical studies for up to five additional pandemic influenza subtypes.

The company initiated a Phase 1/2 study in 2023 to evaluate safety and immunogenicity of mRNA-1018, an investigational pandemic influenza vaccine targeting H5 and H7 avian influenza viruses, in adults aged 18 and older. Following positive preliminary data, Moderna plans to advance mRNA-1018 to Phase 3 trials and will present Phase 1/2 results at an upcoming scientific meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
none
-
Rhea-AI Summary

Moderna reported 2024 product sales of $3.0-3.1 billion (including $1.7B in US) and ended with approximately $9.5B cash balance. The company projects 2025 revenue of $1.5-2.5B, mainly from Spikevax and mRESVIA sales, with an expected year-end cash balance of $6.0B.

The company plans significant cost reductions: $1.0B in 2025 and additional $0.5B in 2026. Key pipeline updates include FDA review of next-generation COVID-19 vaccine (mRNA-1283) with PDUFA date of May 31, 2025, positive Phase 3 data for flu/COVID combination vaccine, and ongoing trials for CMV and norovirus vaccines. The Phase 3 melanoma trial with individualized neoantigen therapy completed enrollment in 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.8%
Tags
none
Rhea-AI Summary

Carisma Therapeutics (NASDAQ: CARM) announced a strategic restructuring, including discontinuation of CT-0525 development and a 34% workforce reduction. The company will redirect focus to its in vivo macrophage engineering platform for fibrosis, oncology, and autoimmune disease therapies.

Key developments include: plans to nominate a liver fibrosis development candidate in Q1 2025; ongoing collaboration with Moderna on multiple oncology and autoimmune programs; and expected restructuring costs of approximately $2.7 million. Three senior executives, including the CFO, General Counsel, and SVP of Human Resources, will depart by December 31, 2024.

The decision to discontinue the anti-HER2 program was based on competitive landscape assessment and recent developments in anti-HER2 therapies affecting antigen loss/downregulation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
none

FAQ

What is the current stock price of Moderna (MRNA)?

The current stock price of Moderna (MRNA) is $31.12 as of March 28, 2025.

What is the market cap of Moderna (MRNA)?

The market cap of Moderna (MRNA) is approximately 12.2B.

What is Moderna's core technology?

Moderna uses a pioneering mRNA platform that instructs patient cells to produce therapeutic proteins, offering a new in vivo drug modality.

Which therapeutic areas does Moderna focus on?

Moderna’s portfolio spans infectious diseases, oncology, rare genetic disorders, and other conditions where traditional therapies may not be effective.

How does Moderna generate revenue?

Revenue is primarily generated through the commercialization of its vaccine products and strategic collaborations in the development of mRNA-based therapies.

What makes Moderna's mRNA platform unique?

The platform allows for rapid design and development of tailored therapeutics, addressing previously undruggable targets with innovative manufacturing processes.

How does Moderna maintain its competitive position?

Moderna leverages a robust intellectual property portfolio, strategic partnerships, operational efficiencies, and a strong clinical pipeline to maintain a competitive edge.

What is the significance of Moderna's COVID-19 vaccine?

The successful development and deployment of its COVID-19 vaccine validated the effectiveness of its mRNA technology, demonstrating its capability in quickly addressing global health challenges.

How does Moderna ensure safety and efficacy in its products?

Moderna adheres to rigorous clinical development protocols and regulatory standards, providing transparent and robust data from its extensive research and trials.

What are the future areas of focus for Moderna?

Moderna continues to enhance its pipeline in areas such as respiratory vaccines, cancer immunotherapies, and treatments for rare diseases, reinforcing its position in innovative medicine.
Moderna

Nasdaq:MRNA

MRNA Rankings

MRNA Stock Data

12.16B
358.52M
7.27%
72.77%
11.68%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE